A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

NCT00300885 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

926

Enrollment

INDUSTRY

Sponsor class

Stopped Based on the results of the interim analysis, it was determined that the study would not meet its primary efficacy endpoint and the study was terminated early.

Conditions

Carcinoma, Non-Small Cell Lung

Interventions

DRUG: Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel
DRUG: Carboplatin plus Paclitaxel

Sponsor

Bayer